Niki BioSolutions Inc(NIKI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 0.6M | Perf Week | 4.63% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | - | Perf Month | -20.01% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 1.16% | Short Float | - | Perf Quarter | -36.42% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | -42.91% | Short Ratio | 0.08 | Perf Half Y | -42.07% |
| Sales | - | P/B | 0.17 | EPS next 5Y | - | ROA | - | Short Interest | 0.01M | Perf YTD | -53.21% |
| Book/sh | 28.38 | P/C | 4.48 | EPS past 3/5Y | 59.28% - | ROE | - | 52W High | -80.85% ($25.90) | Perf Year | -78.62% |
| Cash/sh | 1.11 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 9.72% ($4.52) | Perf 3Y | -76.72% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -1980.9% | Gross Margin | - | Volatility(W/M) | 5.96% 8.19% | Perf 5Y | -98% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.5 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.78 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 40.33 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.78 | Sales Q/Q | - | SMA20 | -2.03% ($5.06) | Beta | 0.18 | Target Price | $230 |
| Payout | - | Debt/Eq | 0.15 | Earnings | - | SMA50 | -28.9% ($6.98) | Rel Volume | 0.05 | Prev Close | $4.73 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -41.48% ($8.48) | Avg Volume(3M) | 0.16M | Price | $4.96 |
| IPO | 2018/12/18 | Option/Short | No/Yes | Trades | 82 | Volume | 7,520 | Change | 4.89% |
Niki BioSolutions IncNIKI | NASD | Biotechnology 🧬 This is a clinical-stage biotech company developing therapeutics for areas of high unmet medical need, such as oncology and infectious diseases. The company was formed through the merger of Apritum Group and Diamir Biosciences and is listed on Nasdaq. It is a micro-cap company developing drug repurposing-based candidates in the early clinical stages.
Over the past 1 year, on the lower side
81% below its 1-year high.
Traded less than usual That is 5% of its average volume.
Holding long would have lost money
Bought 5 years ago, your return today would be -98.0%. The S&P 500 did +79% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.2%.
Tap to view numbers
It ranks #482 of 592 in the industry
Based on market cap of $15M.
BCDA#479 BioCardia Inc $16M PER - 
NCEL#480 NewcelX Ltd $16M PER - 
ALLR#481 Allarity Therapeutics Inc $16M PER - NIKI#482 Niki BioSolutions Inc $15M PER - 
KTTA#483 Pasithea Therapeutics Corp $15M PER - 
FAQ
What kind of company is NIKI?
NIKI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NIKI?
The market cap of NIKI is approximately $15M, ranking 5,349 within its sector.
What is the 52-week high and low for NIKI?
NIKI has recorded a 52-week high of $25.90 and a low of $4.52.
